X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
article (2) 2
humans (2) 2
immunology (2) 2
index medicus (2) 2
abdominal pain - chemically induced (1) 1
aged (1) 1
amylases - blood (1) 1
analysis (1) 1
anti-pd-l1 (1) 1
anti-pd-l1 antibody avelumab (1) 1
antibodies (1) 1
antibodies - blood (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal - genetics (1) 1
antibodies, monoclonal - immunology (1) 1
antibodies, monoclonal - pharmacokinetics (1) 1
antibodies, monoclonal - pharmacology (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibody-dependent cell cytotoxicity - drug effects (1) 1
antibody-dependent cell cytotoxicity - immunology (1) 1
antibody-dependent cellular cytotoxicity (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - immunology (1) 1
antineoplastic agents - pharmacokinetics (1) 1
antineoplastic agents - therapeutic use (1) 1
aspartate aminotransferase (1) 1
aspartate aminotransferases - blood (1) 1
autoimmune diseases - chemically induced (1) 1
b7-h1 antigen - antagonists & inhibitors (1) 1
b7-h1 antigen - metabolism (1) 1
bladder cancer (1) 1
blood (1) 1
cancer (1) 1
cancer therapies (1) 1
carcinoma, transitional cell - drug therapy (1) 1
carcinoma, transitional cell - immunology (1) 1
carcinoma, transitional cell - pathology (1) 1
cell line, tumor (1) 1
cell lung-cancer (1) 1
cell number (1) 1
chills - chemically induced (1) 1
clinical trials (1) 1
creatine (1) 1
creatine kinase (1) 1
creatine kinase - blood (1) 1
ctl-mediated lysis (1) 1
cytotoxicity (1) 1
drug dosages (1) 1
drug evaluation, preclinical (1) 1
dysphonia - chemically induced (1) 1
fatigue (1) 1
fatigue - chemically induced (1) 1
fda approval (1) 1
female (1) 1
fever (1) 1
fever - chemically induced (1) 1
half-life (1) 1
hematology, oncology and palliative medicine (1) 1
immunogenic modulation (1) 1
immunoglobulin g (1) 1
immunoglobulins (1) 1
influenza (1) 1
intravenous administration (1) 1
killer cells, natural - drug effects (1) 1
killer cells, natural - immunology (1) 1
lung cancer (1) 1
lymphocytes t (1) 1
male (1) 1
medical research (1) 1
medicine, experimental (1) 1
melanoma (1) 1
metastases (1) 1
metastasis (1) 1
middle aged (1) 1
monoclonal antibodies (1) 1
monoclonal-antibody (1) 1
msb0010718c (1) 1
multicenter (1) 1
myositis (1) 1
myositis - chemically induced (1) 1
neoplasms - drug therapy (1) 1
nivolumab (1) 1
oncology (1) 1
open-label (1) 1
pain (1) 1
patients (1) 1
pd-1 protein (1) 1
pd-l1 protein (1) 1
pembrolizumab (1) 1
pharmacokinetics (1) 1
protein-serine-threonine kinases - genetics (1) 1
protein-serine-threonine kinases - pharmacology (1) 1
protein-serine-threonine kinases - therapeutic use (1) 1
receptor, transforming growth factor-beta type ii (1) 1
receptors, transforming growth factor beta - genetics (1) 1
receptors, transforming growth factor beta - therapeutic use (1) 1
recombinant fusion proteins - genetics (1) 1
recombinant fusion proteins - pharmacology (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 587 - 598
Journal Article
Urologic Oncology: Seminars and Original Investigations, ISSN 1078-1439, 03/2018, Volume 36, Issue 3, pp. 93.e1 - 93.e11
Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel... 
TGFβ | Immunogenic modulation | Antibody-dependent cellular cytotoxicity | Bladder cancer | Anti-PD-L1 | CTL-mediated lysis | Receptors, Transforming Growth Factor beta - genetics | Recombinant Fusion Proteins - pharmacology | Humans | Recombinant Fusion Proteins - therapeutic use | Antibody-Dependent Cell Cytotoxicity - immunology | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | T-Lymphocytes, Cytotoxic - drug effects | Urologic Neoplasms - pathology | Receptor, Transforming Growth Factor-beta Type II | Urologic Neoplasms - drug therapy | Receptors, Transforming Growth Factor beta - therapeutic use | Killer Cells, Natural - immunology | Drug Evaluation, Preclinical | T-Lymphocytes, Cytotoxic - immunology | Tumor Microenvironment - drug effects | Antibodies, Monoclonal - pharmacology | Protein-Serine-Threonine Kinases - genetics | Urologic Neoplasms - immunology | Protein-Serine-Threonine Kinases - therapeutic use | Tumor Microenvironment - immunology | Antibodies, Monoclonal - genetics | B7-H1 Antigen - metabolism | B7-H1 Antigen - antagonists & inhibitors | Carcinoma, Transitional Cell - pathology | Carcinoma, Transitional Cell - immunology | Carcinoma, Transitional Cell - drug therapy | Cell Line, Tumor | Recombinant Fusion Proteins - genetics | Killer Cells, Natural - drug effects | Antibody-Dependent Cell Cytotoxicity - drug effects | Protein-Serine-Threonine Kinases - pharmacology | anti-PD-L1
Journal Article
01/2012, ISBN 1267996986
Human herpesvirus 8 (HHV-8) is a lymphotropic gammaherpesvirus that causes Kaposi's sarcoma (KS), a vascular tumor of spindle-shaped endothelial cells. The... 
Immunology | Virology
Dissertation
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.